AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)

“MONTREAL , May 23, 2019 /CNW/ – AbbVie (ABBV), a global, research and development-driven biopharmaceutical company, announced today that Ontario is the first province to reimburse VENCLEXTA® (venetoclax) monotherapy under its Drugs and Devices Division’s (DDD) Exceptional Access Program effective May 13, 2019 .ⁱⁱVENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have no other treatment options. VENCLEXTA is an oral, once-daily medicine.”

Read the full news release here:

https://finance.yahoo.com/news/abbvie-reaches-agreement-pan-canadian-130000070.html?soc_src=social-sh&soc_trk=ma

New Test Approved for Payment by Medicare for Measuring Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukemia or CLL
January 12, 2020

The FDA announced Breakthrough Therapy Designation (BTD) for acalabrutinib (Calquence) as a single agent to treat chronic lymphocytic leukemia (CLL)
August 15, 2019

Shuttering of the Biden Cancer Initiative
August 5, 2019

Approval of a biosimilar for Rituximab
July 29, 2019

May 15, 2019: FDA approved venetoclax in combination with obinutuzumab for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
May 20, 2019

FDA places a partial hold on all venetoclax clinical trials for multiple myeloma (MM) patients
March 20, 2019